公开(公告)号：WO2013109388A3

公开(公告)日：2015-02-05

申请号：PCT/US2012071434

申请日：2012-12-21

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： MATSUO YO ,  HISADA SHOJI ,  NAKAMURA YUSUKE ,  AHMED FERYAN ,  WALKER JOEL R ,  HUNTLEY RAYMOND

IPC: A61K31/435 ,  A61K31/4353 ,  A61K31/4375 ,  C07D471/04

CPC classification number: A61K31/5377 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/506 ,  C07D471/04

Abstract: The present invention directs to a compound represented by Formula (I), comprising a 1,5-naphthyridine derivative. In one embodiment the 1,5-naphthyridine derivative of Formula (I) has an inhibitory activity against maternal embryonic leucine zipper kinase (MELK). The present invention also includes a method for preparing the 1,5-naphthyridine derivative of Formula (I). The present invention also includes a pharmaceutical composition containing the 1,5-naphthyridine derivative of Formula (I) as an active ingredient.

Abstract translation: 本发明涉及由式（I）表示的化合物，其包含1,5-萘啶衍生物。 在一个实施方案中，式（I）的1,5-萘啶衍生物对母体的亮氨酸亮氨酸拉链激酶（MELK）具有抑制活性。 本发明还包括制备式（I）的1,5-二氮杂萘衍生物的方法。 本发明还包含含有式（I）的1,5-二氮杂萘衍生物作为活性成分的药物组合物。

公开(公告)号：WO2013109388A8

公开(公告)日：2013-09-26

申请号：PCT/US2012071434

申请日：2012-12-21

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： MATSUO YO ,  HISADA SHOJI ,  NAKAMURA YUSUKE ,  AHMED FERYAN ,  WALKER JOEL R ,  HUNTLEY RAYMOND

IPC: A61K31/4745 ,  C07D471/04

CPC classification number: A61K31/5377 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/506 ,  C07D471/04

Abstract: The present invention directs a compound represented by formula (I).

Abstract translation: 本发明指出了由式（I）表示的化合物。

公开(公告)号：MX381489B

公开(公告)日：2025-03-12

申请号：MX2018003903

申请日：2018-03-28

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： SATYANARAYANA ARVAPALLI VENKATA ,  CHAKRABARTI ANJAN ,  HISADA SHOJI ,  DECORNEZ HÉLÈNE ,  MATSUO YO ,  RAWAT MANISH ,  NAKAMURA YUSUKE ,  RAI SANJAY ,  RAVULA SRINIVAS ,  TALUKDAR ARINDAM ,  DUAN ZHIYONG

IPC: C07D487/04 ,  A61K31/4745 ,  A61P35/00 ,  C07D451/00 ,  C07D471/04 ,  C07D519/00

Abstract: La presente invención se refiere a un compuesto representado por la fórmula (I). (ver Fórmula).

公开(公告)号：BR112013002182B1

公开(公告)日：2022-05-03

申请号：BR112013002182

申请日：2011-07-28

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： AHMED FERYAN ,  DECORNEZ HELENE ,  JOEL R WALKER ,  HUNTLEY RAYMOND ,  HISADA SHOJI ,  MATSUO YO ,  NAKAMURA YUSUKE

IPC: A61K31/47 ,  A61P35/00 ,  A61P43/00 ,  C07D215/46 ,  C07D215/54 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D409/04 ,  C07D409/06 ,  C07D409/14 ,  C07D413/06 ,  C07D453/02 ,  C07D471/04

Abstract: compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos a presente invenção se refere a um composto derivado de quinolina para inibir a atividade de melk, um método para a preparação do mesmo, e uma composição farmacêutica contendo o com posto como um ingrediente ativo, o qual é representado pela fórmula (i): (i) ou um sal farmaceuticamente aceitável do mesmo, visto que melk, cinase de zíper de leucina embrionária materna, foi previamente identificada como um novo membro da família de snf1/ampk serina-treonina cinase que está envolvida no desenvolvimento embrionário de mamífero. o gene foi mostra do desempenhar um papel importante na renovação de célula tronco, sendo que, melk, recentemente, mostrou ser super-regulada em câncer de mama, células de câncer de pulmão, bexiga, linfoma e cervical.

公开(公告)号：CA2857346C

公开(公告)日：2019-06-04

申请号：CA2857346

申请日：2012-12-21

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： MATSUO YO ,  HISADA SHOJI ,  NAKAMURA YUSUKE ,  AHMED FERYAN ,  WALKER JOEL R ,  HUNTLEY RAYMOND

IPC: C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/506 ,  A61P35/00 ,  C07D519/00

Abstract: The present disclosure relates to a 1,5-naphthyridine derivative having an inhibitory activity against MELK, a method for the preparation of same and a pharmaceutical composition containing same, and more particularly to a compound represented by formula (I) (See Formula I)

公开(公告)号：CA2999852A1

公开(公告)日：2017-04-06

申请号：CA2999852

申请日：2016-09-12

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： MATSUO YO ,  HISADA SHOJI ,  NAKAMURA YUSUKE ,  CHAKRABARTI ANJAN ,  RAWAT MANISH ,  RAI SANJAY ,  SATYANARAYANA ARVAPALLI VENKATA ,  DUAN ZHIYONG ,  TALUKDAR ARINDAM ,  RAVULA SRINIVAS ,  DECORNEZ HELENE

IPC: A01N43/90

Abstract: The present invention directs to a compound represented by formula (I).

公开(公告)号：AU2012366148A1

公开(公告)日：2014-06-05

申请号：AU2012366148

申请日：2012-12-21

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： MATSUO YO ,  HISADA SHOJI ,  NAKAMURA YUSUKE ,  AHMED FERYAN ,  WALKER JOEL R ,  HUNTLEY RAYMOND

IPC: C07D471/04 ,  A61K31/4745

Abstract: The present invention directs a compound represented by formula (I).

公开(公告)号：CA2857346A1

公开(公告)日：2013-07-25

申请号：CA2857346

申请日：2012-12-21

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： MATSUO YO ,  HISADA SHOJI ,  NAKAMURA YUSUKE ,  AHMED FERYAN ,  WALKER JOEL R ,  HUNTLEY RAYMOND

IPC: C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/506 ,  A61P35/00 ,  C07D519/00

Abstract: The present invention directs a compound represented by formula (I).

公开(公告)号：AU2011235319A1

公开(公告)日：2012-10-11

申请号：AU2011235319

申请日：2011-03-29

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： NAKAMURA YUSUKE ,  MATSUO YO ,  HISADA SHOJI ,  AHMED FERYAN ,  HUNTLEY RAYMOND ,  SAJJADI-HASHEMI ZOHREH ,  JENKINS DAVID M ,  KARGBO ROBERT B ,  CUI WENGE ,  GAUUAN POLIVINA JOLICIA F ,  WALKER JOEL R ,  DECORNEZ HELENE ,  GURRAM MAHENDER

IPC: A01N43/42 ,  C07D221/06

Abstract: Trycyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.

公开(公告)号：ZA201104487B

公开(公告)日：2012-03-28

申请号：ZA201104487

申请日：2011-06-17

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： MATSUO YO ,  OHSAWA RYUJI ,  HISADA SHOJI

IPC: A61K20060101 ,  A61P20060101 ,  C07D20060101

Abstract: GSK-3beta inhibitors comprising 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives are provided. For example, the inhibitors have following general formula (I).